Compared to the standard shot, the mRNA vaccine had an overall vaccine efficacy that was 26.6 percent higher, and 27.4 ...

The Cambridge biotech believes packaging the two immunizations together will lead to higher uptake of COVID vaccines.

The phase three study data clears the path forward for Moderna’s combination jab targeting Covid-19 and influenza.

Moderna Inc. said Monday its experimental flu shot showed positive results in a late-stage trial.   In a Phase 3 study, the ...

Moderna said on Monday its experimental influenza vaccine was found to be 26.6% more effective than a currently approved ...

Moderna’s new flu vaccine, based on the same mRNA technology used in its COVID-19 shot, showed promising results in a major trial.

The biotechnology company’s messenger RNA flu vaccine candidate showed positive results in a late-stage trial.

Moderna said that the result – which showed its shot was around 26.6% more effective than the comparator – sets up regulatory filings both for mRNA-1010 and its combination flu and COVID-19 ...

Moderna said its own vaccine, dubbed mRNA-1010, had achieved a relative vaccine efficacy (rVE) of 26.6% over a “licensed standard-dose seasonal influenza vaccine” in the study of 40,805 adults ...

Moderna has reported positive phase 3 results for its seasonal flu vaccine, mRNA-1010, which outperformed a standard-dose licensed influenza vaccine in adults aged 50 and older. The study, known as ...

Moderna Inc. said Monday its experimental flu shot showed positive results in a late-stage trial. In a Phase 3 study, the company’s mRNA-1010 flu vaccine’s efficacy was nearly 27 percent ...